Omega Diagnostics Group PLC AbC-19 monitors vaccine response to variants

TIDMODX

Omega Diagnostics Group PLC

27 July 2021

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

AbC-19(TM) test to monitor vaccine responses to variants of concern

AbC-19(TM) able to detect antibody response to different vaccines as well as natural infection

Omega (AIM: ODX), the medical diagnostics company focused on Global Health (CD4 and COVID-19) and Health and Nutrition, notes the publication of an article illustrating the use of the AbC-19(TM) rapid antibody test ("AbC-19(TM)"), semi-quantitively, to monitor antibody responses against variants of concern. The AbC-19(TM) is a lateral flow test for the detection of neutralising IgG antibodies to the full trimeric spike protein of the SARS-CoV-2 virus.

The article demonstrates that the AbC-19(TM) is able to monitor antibody response following vaccination or natural infection. The paper shows differences in strength of antibody response with the Pfizer and AstraZeneca ("AZ") vaccines and the induced antibody responses to the original Wuhan variant, on which the vaccines are based. It also shows that these antibodies cross-react to the 'spike protein' of different variants of concern. This study was conducted using the AbC-19(TM) and prototypes based on different covid variants. The results demonstrated a stronger antibody response in those vaccinated by Pfizer, compared to AZ, whilst noting the cohort vaccinated with AZ were older, which the authors noted may have an effect on antibody response.

The authors used a semi-quantitative score card to record the strength of the test-line response on the AbC-19(TM) . They illustrated pictorially, and in graphical format, a proportional response of line intensity to the concentrations of neutralising antibodies in a serial dilution of the WHO standard 20/136 from 1000 IU/mL down to 7.8 IU/mL which covers the range that previous research has shown to be indicative of immunity. The WHO standard 20/136 is for the calibration and harmonization of serological assays detecting anti-SARS-CoV-2 neutralising antibodies.

The article by researchers at the University of Birmingham is published as: Ebanks, D et al, "Cross reactivity of serological response to SARS-CoV-2 vaccination with viral variants of concern detected by lateral flow immunoassays" Journal of Infection on 26 July 2021.

The full paper can be viewed here: https://www.sciencedirect.com/science/article/abs/pii/S0163445321003637

Contacts:

 
 Omega Diagnostics Group PLC                             www.omegadiagnostics.com 
 Colin King, Chief Executive                                      via Walbrook PR 
 Kieron Harbinson, Group Finance 
  Director 
 
 finnCap Ltd                                                   Tel: [phone] 
 Geoff Nash/Edward Whiley (Corporate 
  Finance) 
 Alice Lane (ECM) 
 
 Walbrook PR Limited                   Tel: [phone] or [e-mail] 
 Paul McManus                                                  Mob: [phone] 
 Lianne Cawthorne                                              Mob: [phone] 
 

About the UK-RTC

The UK Rapid Test Consortium (UK-RTC) was founded in response to a UK Government call for businesses to work together on a rapid antibody test to be rolled out nationally. Led by Abingdon Health, it's members also include, BBI Solutions, CIGA Healthcare and Omega Diagnostics. The Abc-19(TM) is approved in Europe and the UK for professional use and is available for sale.

About the AbC-19(TM) Rapid Test

The AbC-19(TM) Rapid Test is a single use test for the detection of neutralising IgG antibodies to the full trimeric spike protein of the SARS-CoV-2 virus in human capillary whole blood.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAFIFFEDFIDFIL

(END) Dow Jones Newswires

July 27, 2021 02:00 ET (06:00 GMT)